www.cddep.org/resistancemap
ANTIBIOTIC USE AND RESISTANCE AT A GLANCE: 1999–2010 THERE ARE LARGE DIFFERENCES IN PRESCRIBING ANTIBIOTICS STATE-BY-STATE
1,196 1,177 1,159 1,136 1,122 1,079 1,020 976 961 956 950 935 932 921 906 880 879 875 874 867 854 852 851 840 836 834 821 818 801 797 790 787 768 758 744 732 715 706 689 679 677 654 637 636 626 619 611 571 556 554 543 510
In 2010 states in the East South Central region filled over twice as many prescriptions per capita as Pacific states. How does your state compare?
National Average
KY TN LA AK KS ND MO MI RI OH OK IA WV MS AL DC IN NE DE SC NJ
IL
CT
MA PA MD AZ FL MN ME MT NH WA CA AK
TX GA NY SD NC
UT VA WY WI NM ID NV VT CO OR HI
Prescriptions per 1,000 people
1100–1199
1000–1099
900–999
800–899
700–799
600–699
500–599
DECREASE IN PRESCRIBING WAS NOT UNIFORM ACROSS STATES Widening regional gap: East South Central states are making little progress. NH
National Average –17% VT
WA MT OR
ME
ND
ID
MN
MA
WI
SD IA
NE
NV UT CA
AZ
KS
WV KY
DE
NC
AR
MD
SC GA
AL
MS
NJ
VA VA
TN
TX
CT
OH
IN
MO
OK
NM
RI
PA IL
CO
NY
MI
WY
DC
LA FL
AK
HI
Percent change in use (1999–2010)
2 to –6
–7 to –15
–16 to –24
–25 to –33
THE COMPOSITION OF ANTIBIOTIC USE IS CHANGING Although the number of prescriptions per capita decreased, there has been a shift towards newer, more powerful antibiotic classes. 8% 8%
7%
8% 36%
31%
9%
1999
2010
966
801
prescriptions per 1,000 people
12%
prescriptions per 1,000 people
18% 14% 27% 22%
Penicillins
Macrolides
Cephalosporins
Fluoroquinolones
Tetracyclines
Tmp-smx
(Amoxil)
(Z-pack)
(Keflex)
(Cipro)
(Doxy)
(Bactrim)
The relative increase in the use of antibiotics with a broader spectrum such as fluoroquinolones or macrolides is troubling because it accelerates the rise of bacterial resistance.
COMMON INFECTIONS ARE BECOMING MORE DRUG-RESISTANT
Drug Resistance Index
Urinary tract infections are harder to treat with currently available antibiotics, while skin infections are responding to new therapies.
Time
Urinary Infections
Skin Infections
In addition to using currently available antibiotics responsibly, we urgently need to develop new drugs to treat the types of infections that are becoming harder to treat.
For more information, visit us at WWW.CDDEP.ORG/RESISTANCEMAP Antibiotic The statements, findings, conclusions, views, and opinions contained and expressed herein are based in part on data obtained under license from the following IMS Health Incorporated information service: Xponent™, January 1999–December 2010, IMS Health Incorporated. All rights reserved. Such statements, findings, conclusions, views, and opinions are not necessarily those of IMS Health Incorporated or any of its affiliated or subsidiary entities.